Vertex insider plans sale of 2,031 common shares
Vertex Pharmaceuticals executive Edward Atkinson has filed a notice of proposed share sales under Rule 144.
Rhea-AI Filing Summary
Vertex Pharmaceuticals executive Edward Atkinson has filed a notice of proposed share sales under Rule 144. The filing covers the planned sale of 2,031 shares of Vertex common stock through Fidelity Brokerage Services LLC on or about 02/17/2026 on NASDAQ, with an aggregate market value of 994093.26 at the time of the notice.
The 2,031 shares to be sold were acquired on 02/13/2026 via restricted stock vesting from the issuer as compensation. Over the past three months, Atkinson has already sold 2,500 Vertex common shares on 11/17/2025 for gross proceeds of 1086450.00, and 1,751 shares on 02/11/2026 for gross proceeds of 806212.93. The filing also notes that the seller represents not being aware of undisclosed material adverse information about the company.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the VRTX Form 144 filing by Edward Atkinson disclose?
What VRTX stock sales has Edward Atkinson made in the past three months?
Does the VRTX Form 144 include any representation about inside information?
AI-generated analysis. How Rhea-AI works. Not financial advice.